AnaptysBio’s Pivotal Legal Battle and Corporate Split on the Horizon
Published on 01/27/2026 at 14:32 | Redaktion boerse-global.de
Shares of AnaptysBio are trading marginally lower than the previous session’s close. The company’s valuation is currently tethered to a high-stakes legal dispute with Tesaro, now part of GSK, concerning royalties for the cancer drug Jemperli. A trial scheduled for July is anticipated to bring substantial clarity to the financial implications of this case.
According to preliminary figures, AnaptysBio reported a strong liquidity position of approximately $310 million in cash and investments as of December 31, 2025. This financial backbone supports the company’s ambitious plan to separate into two publicly traded entities by the end of 2026. The split aims to create a dedicated Royalty Management Company to oversee royalty cash flows Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
